Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Targeted Inhibition of mTORC1 and mTORC2 by the Active-Site mTOR Inhibitors, PP-242 and OSI-027, Has Cytotoxic Effects In T-Cell Acute Lymphoblastic Leukemia

Camilla Evangelisti, PhD, Francesca Chiarini, PhD, Francesca Ricci, BS, Pierluigi Tazzari, MD, Andrea Pession, MD, PhD, James A McCubrey, PhD, Alberto M. Martelli, MD

Blood (2010) 116 (21): 3242.

https://doi.org/10.1182/blood.V116.21.3242.3242

Published: 2010

Journal Articles

Dual Inhibition of Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin with NVP-BEZ235 as a New Therapeutic Option for T-Cell Acute Lymphoblastic Leukemia.

Francesca Chiarini, BS, Cecilia Grimaldi, BS, Francesca Ricci, BS, Pierluigi Tazzari, MD, Camilla Evangelisti, PhD, Andrea Pession, MD, PhD, Pasqualepaolo Pagliaro, MD, James McCubrey, PhD, Alberto M. Martelli, MD

Blood (2009) 114 (22): 2025.

https://doi.org/10.1182/blood.V114.22.2025.2025

Published: 2009

Journal Articles

Synergistic Proapoptotic Activity of Recombinant TRAIL Plus the Akt Inhibitor Perifosine in Acute Myelogenous Leukemia Cells-a Novel Therapeutic Approach for Leukemia Displaying Elevated Akt Signaling.

PierLuigi Tazzari, MD, Veronica Papa, BS, Francesca Ricci, BS, Francesca Chiarini, BS, Camilla Evangelisti, PhD, Giovanni Martinelli, MD, Andrea Bontadini, MD, James McCubrey, PhD, Alberto M. Martelli, MD

Blood (2008) 112 (11): 957.

https://doi.org/10.1182/blood.V112.11.957.957

Published: 2008

Journal Articles

Roles of Raf/MEK/ERK and PI3K/Akt/mTOR Pathways in Prevention of Apoptosis and Induction of Drug Resistance in Myeloid Hematopoietic Cells.

Steve L. Abrams, BS, Camilla Evangelisti, PhD, Francesca Chiarini, BS, Negin Misaghian, BS, Jorg Basecke, MD, Michele Millela, MD, Agostino Tafuri, MD, Massimo Libra, MD, Franca Stivala, MD, Marina Konopleva, MD, Michael Andreeff, MD, Linda S. Steelman, MS, Jacob Troppmair, PhD, Alberto M. Martelli, MD, James A. McCubrey, PhD

Blood (2007) 110 (11): 641.

https://doi.org/10.1182/blood.V110.11.641.641

Published: 2007

Journal Articles

The Novel Akt Inhibitor Perifosine Induces Apoptosis, Cell Cycle Arrest and Synergizes with Chemotherapeutic Drugs in Acute Myelogenous Leukemia Cells by a JNK Dependent Mechanism - A Novel Therapeutic Approach for Leukemia Displaying Elevated Akt Signaling.

Alberto M. Martelli, MD, PhD, Veronica Papa, BS, Pier Luigi Tazzari, MD, Francesca Chiarini, BS, Alessandra Cappellini, PhD, Francesca Ricci, BS, Anna Maria Billi, PhD, Camilla Evangelisti, PhD, Steve L. Abrams, BS, Emanuela Ottaviani, PhD, Giovanni Martinelli, MD, James A. McCubrey, PhD

Blood (2007) 110 (11): 3355.

https://doi.org/10.1182/blood.V110.11.3355.3355

Published: 2007

NARROW

Targeted Inhibition of mTORC1 and mTORC2 by the Active-Site mTOR Inhibitors, PP-242 and OSI-027, Has Cytotoxic Effects In T-Cell Acute Lymphoblastic Leukemia

Dual Inhibition of Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin with NVP-BEZ235 as a New Therapeutic Option for T-Cell Acute Lymphoblastic Leukemia.

Synergistic Proapoptotic Activity of Recombinant TRAIL Plus the Akt Inhibitor Perifosine in Acute Myelogenous Leukemia Cells-a Novel Therapeutic Approach for Leukemia Displaying Elevated Akt Signaling.

Roles of Raf/MEK/ERK and PI3K/Akt/mTOR Pathways in Prevention of Apoptosis and Induction of Drug Resistance in Myeloid Hematopoietic Cells.

The Novel Akt Inhibitor Perifosine Induces Apoptosis, Cell Cycle Arrest and Synergizes with Chemotherapeutic Drugs in Acute Myelogenous Leukemia Cells by a JNK Dependent Mechanism - A Novel Therapeutic Approach for Leukemia Displaying Elevated Akt Signaling.

Email alerts

ASH Publications

American Society of Hematology

Targeted Inhibition of mTORC1 and mTORC2 by the Active-Site mTOR Inhibitors, PP-242 and OSI-027, Has Cytotoxic Effects In T-Cell Acute Lymphoblastic Leukemia

Dual Inhibition of Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin with NVP-BEZ235 as a New Therapeutic Option for T-Cell Acute Lymphoblastic Leukemia.

Synergistic Proapoptotic Activity of Recombinant TRAIL Plus the Akt Inhibitor Perifosine in Acute Myelogenous Leukemia Cells-a Novel Therapeutic Approach for Leukemia Displaying Elevated Akt Signaling.

Roles of Raf/MEK/ERK and PI3K/Akt/mTOR Pathways in Prevention of Apoptosis and Induction of Drug Resistance in Myeloid Hematopoietic Cells.

The Novel Akt Inhibitor Perifosine Induces Apoptosis, Cell Cycle Arrest and Synergizes with Chemotherapeutic Drugs in Acute Myelogenous Leukemia Cells by a JNK Dependent Mechanism - A Novel Therapeutic Approach for Leukemia Displaying Elevated Akt Signaling.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only